---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-000499"
form_type: "8-K"
ticker: "GNPX"
cik: "0001595248"
company_name: "Genprex, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:38:32.889264+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Genprex enters exclusive license with University of Pittsburgh for Type 2 diabetes gene therapy

## Summary
- Genprex (GNPX) licensed worldwide exclusive rights to gene therapy using Pdx1 and MafA genes for Type 2 diabetes from University of Pittsburgh.
- License includes milestone payments up to $4.0 million, single-digit royalties, and a low double-digit share of sublicense income.
- The GPX-003 technology aims to rejuvenate beta cells to increase insulin expression; preclinical data accepted for oral presentation at ATTD 2023.
- This is the third diabetes technology license from University of Pittsburgh in 2022, covering both Type 1 (GPX-002) and Type 2 diabetes programs.

## SEC filing metadata
- accession: 0001437749-23-000499
- form_type: 8-K
- ticker: GNPX
- cik: 0001595248
- company_name: Genprex, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595248/000143774923000499/0001437749-23-000499-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595248/000143774923000499/gnpx20230103_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-000499
- JSON: https://secwatch.observer/filing/0001437749-23-000499.json
- Plain text: https://secwatch.observer/filing/0001437749-23-000499.txt

## Key facts
- Material Agreements
  Genprex, Inc. entered into UP License Agreement with University of Pittsburgh - Of the Commonwealth System of Higher Education valued at approximately $4,000,000 (effective 2022-12-29).
  - Action: entry
  - Agreement: license
  - Counterparty: University of Pittsburgh - Of the Commonwealth System of Higher Education
  - Value: approximately $4,000,000
  - Effective: 2022-12-29
  source text: As consideration for the UP License Agreement, Genprex agreed to pay UP an initial license fee, annual maintenance fees, running single digit royalties, minimum annual royalties in a fixed cash amount, a low double digit percentage share of non-royalty sublicense income, and certain milestone payments up to an aggregate of approximately $4,000,000, as well as patent prosecution expenses incurred prior to and after the effective date of the UP License Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1595248/000143774923000499/0001437749-23-000499-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.